Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
29 04 2022
Historique:
received: 31 03 2022
revised: 19 04 2022
accepted: 20 04 2022
entrez: 27 5 2022
pubmed: 28 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

Inuit are the Indigenous Arctic peoples and residents of the Canadian territory of Nunavut who have the highest global rate of lung cancer. Given lung cancer's mortality, histological and genomic characterization was undertaken to better understand the disease biology. We retrospectively studied all Inuit cases from Nunavut's Qikiqtani (Baffin) region, referred to the Ottawa Hospital Cancer Center between 2001 and 2011. Demographics were compiled from medical records and tumor samples underwent pathologic/histologic confirmation. Tumors were analyzed by next generation sequencing (NGS) with a cancer hotspot mutation panel. Of 98 patients, the median age was 66 years and 61% were male. Tobacco use was reported in 87%, and 69% had a history of lung disease (tuberculosis or other). Histological types were: non-small cell lung carcinoma (NSCLC), 81%; small cell lung carcinoma, 16%. Squamous cell carcinoma (SCC) represented 65% of NSCLC. NGS on 55 samples demonstrated mutation rates similar to public lung cancer datasets. In SCC, the

Identifiants

pubmed: 35621648
pii: curroncol29050258
doi: 10.3390/curroncol29050258
pmc: PMC9139845
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3171-3186

Références

N Engl J Med. 2005 Jul 14;353(2):123-32
pubmed: 16014882
Lung Cancer. 2014 Oct;86(1):22-8
pubmed: 25172266
Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):29-34
pubmed: 1845165
N Engl J Med. 2014 Mar 27;370(13):1189-97
pubmed: 24670165
Curr Oncol. 2015 Jun;22(3):e164-70
pubmed: 26089727
Health Rep. 2017 Feb 15;28(2):10-14
pubmed: 28198984
Lancet Oncol. 2008 Sep;9(9):892-900
pubmed: 18760245
Curr Oncol. 2015 Aug;22(4):246-51
pubmed: 26300662
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
PLoS One. 2011 Mar 31;6(3):e17479
pubmed: 21483846
Oncogene. 2007 Aug 30;26(40):5911-8
pubmed: 17384680
Am J Pathol. 1999 Mar;154(3):677-81
pubmed: 10079245
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
J Thorac Oncol. 2011 Jan;6(1):32-7
pubmed: 21150470
Cancer Sci. 2007 Nov;98(11):1747-51
pubmed: 17711506
Hum Mol Genet. 2005 May 15;14(10):1283-92
pubmed: 15800014
Nature. 2007 Aug 16;448(7155):807-10
pubmed: 17676035
Lung Cancer. 2014 Apr;84(1):13-22
pubmed: 24524818
Int J Cancer. 2012 Sep 1;131(5):1210-9
pubmed: 22052329
Tob Control. 2008 Jun;17(3):198-204
pubmed: 18390646
J Thorac Oncol. 2016 Jun;11(6):838-49
pubmed: 26917230
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Thorac Oncol. 2015 Feb;10(2):250-5
pubmed: 25376516
Chest. 1997 May;111(5):1414-6
pubmed: 9149602
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
Genome Biol. 2011 Dec 20;12(12):R124
pubmed: 22185227
Int J Circumpolar Health. 2016 Jan 12;75:29787
pubmed: 26765259
J Thorac Oncol. 2008 Aug;3(8):819-31
pubmed: 18670299
Oncogene. 2009 Apr 30;28(17):1928-38
pubmed: 19330024
Nature. 2015 Oct 15;526(7573):361-70
pubmed: 26469047
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Cancer Res. 2002 Jul 1;62(13):3659-62
pubmed: 12097271
Cancer Res. 2000 Feb 1;60(3):546-8
pubmed: 10676634
Cancer Invest. 2009 May;27(4):407-16
pubmed: 19229701
Br J Cancer. 2008 Jul 22;99(2):245-52
pubmed: 18594528
Ann Intern Med. 1986 Oct;105(4):503-7
pubmed: 3752756
PLoS Med. 2016 Dec 6;13(12):e1002162
pubmed: 27923066
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer. 2011 Feb 1;117(3):618-24
pubmed: 20886634
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Bioinformatics. 2012 Jan 15;28(2):167-75
pubmed: 22084253
Nat Rev Cancer. 2007 Oct;7(10):778-90
pubmed: 17882278

Auteurs

Glenwood D Goss (GD)

The Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Center and the University of Ottawa, ON K1N 6N5, Canada.

Johanna N Spaans (JN)

The Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.

David Huntsman (D)

Imagia Canexia Health, Suite #204 Donald Rix Building, 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.

Timothy Asmis (T)

Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Center and the University of Ottawa, ON K1N 6N5, Canada.

Natalie M Andrews Wright (NM)

The Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.

Marc Duciaume (M)

The Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.

Pardeep Kaurah (P)

Imagia Canexia Health, Suite #204 Donald Rix Building, 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.
Department of Medical Genetics, Faculty of Medicine, University of British Columbia, and Hereditary Cancer Program, BC Cancer, Vancouver, BC V5Z 4E6, Canada.

Ruth R Miller (RR)

Imagia Canexia Health, Suite #204 Donald Rix Building, 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.

Shantanu Banerji (S)

CancerCare Manitoba Research Institute, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.

Harmanjatinder S Sekhon (HS)

The Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
Department of Pathology, The Ottawa Hospital and the University of Ottawa, Ottawa, ON K1N 6N5, Canada.

Marcio M Gomes (MM)

The Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
Department of Pathology, The Ottawa Hospital and the University of Ottawa, Ottawa, ON K1N 6N5, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH